Salsalate is the generic name of a prescription drug marketed under thebrandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[1]
The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition ofIκB kinase resulting in decreased action ofNF-κB genes.[2][3][4] This mechanism is thought to be responsible for salsalate'sinsulin-sensitizing andblood sugar lowering properties.[3]
The risk ofbleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated withaspirin use.[3]
Salsalate has been proposed for the prevention and treatment oftype 2 diabetes mellitus due to its ability to lowerinsulin resistance associated with inflammation and may be useful inprediabetes.[2] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[2]
This sectionis missing information about first known synthesis and commercialization — who decided to stick two salicylic acid molecules together?. Please expand the section to include this information. Further details may exist on thetalk page.(January 2023)
Salsalate had been suggested as possible treatment for diabetes as early as 1876.[2][6][7]
^abcEsser N, Paquot N, Scheen AJ (March 2015). "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease".Expert Opinion on Investigational Drugs (Review).24 (3):283–307.doi:10.1517/13543784.2015.974804.PMID25345753.S2CID23674166.
^Ebstein W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben".Berliner Klinische Wochenschrift.13:337–340.
^Baker W, Ollis WD, Zealley TS (1951). "42. Eight- and higher-membered ring compounds. Part II. Di-, tri-, tetra-, and hexa-salicylides".Journal of the Chemical Society (Resumed): 201.doi:10.1039/JR9510000201.
^DE 211403, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure aus Salicylsäure oder ihrne Salzen [Process for preparing a crystallized salicylosalicylic acid from salicylic acid or its salts]", published 1909-06-25, assigned to C.F. Boehringer & Söhne
^DE 214044, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure [Process for preparing a crystallized salicylosalicylic acid]", published 1909-09-20, assigned to C.F. Boehringer & Söhne